Dilated Cardiomyopathy 1O (CMD1O): Disease-Characteristics Research Report

Executive summary and evidence warning

Dilated cardiomyopathy 1O (CMD1O) is the historical designation for an adult-onset dilated-cardiomyopathy/ventricular-arrhythmia phenotype attributed to heterozygous variants in ABCC9, which encodes the cardiac ATP-sensitive potassium-channel regulatory subunit SUR2A. Its identifiers are MONDO:0012062 and OMIM #608569. The foundational report found only two ABCC9 variants among 323 people with idiopathic DCM, although both altered channel behavior in functional assays. Modern evidence appraisal is therefore crucial: a 2024 review reports the autosomal-dominant ABCC9–DCM relationship as ClinGen Limited, not Strong or Definitive. CMD1O should consequently be represented as a historically asserted, biologically plausible but incompletely validated Mendelian disease entity—not as an unqualified, firmly established monogenic diagnosis. (bienengraeber2004abcc9mutationsidentified pages 2-2, micolonghi2024unveilingthespectrum pages 25-26, micolonghi2024unveilingthespectrum pages 8-9)

The strongest disease-specific evidence remains Bienengraeber et al., Nature Genetics, online 21 March 2004/April 2004, DOI 10.1038/ng1329, PMID 15034580. The authors’ abstract states: “Scanning of genomic DNA from individuals with heart failure and rhythm disturbances due to idiopathic dilated cardiomyopathy identified two mutations in ABCC9,” and concludes that defective pore regulation is “a mechanism for channel dysfunction and susceptibility to dilated cardiomyopathy.” The wording “susceptibility” is appropriate given the limited human-genetic evidence. (bienengraeber2004abcc9mutationsidentified pages 2-2, bienengraeber2004abcc9mutationsidentified pages 1-2)

Table: A compact, database-oriented summary of CMD1O identity, foundational human evidence, current gene-validity concerns, mechanism, models, diagnosis, and treatment.

1. Disease information

Definition

CMD1O denotes DCM associated historically with ABCC9/SUR2A dysfunction. DCM itself is defined by left-ventricular, or sometimes biventricular, dilatation with global or regional systolic dysfunction that is not adequately explained by coronary artery disease or abnormal loading from hypertension, valve disease, or congenital heart disease. Ventricular arrhythmia—particularly ventricular tachycardia—was prominent in the original CMD1O cases. (olson2010humankatpchannelopathies pages 5-6, sorella2025diagnosisandmanagement pages 1-2, sorella2025diagnosisandmanagement pages 2-3)

Identifiers and synonyms

• MONDO: MONDO:0012062.
• OMIM phenotype: #608569.
• Gene: ABCC9; OMIM gene 601439; Ensembl ENSG00000069431.
• Preferred/synonymous labels: dilated cardiomyopathy 1O; cardiomyopathy, dilated, 1O; CMD1O; DCM1O; ABCC9-related dilated cardiomyopathy.
• MeSH: use the parent concept Cardiomyopathy, Dilated; no uniquely specific CMD1O MeSH descriptor was identified.
• ICD-10-CM: use the general DCM code I42.0; there is no CMD1O-specific code.
• ICD-11: classify under dilated cardiomyopathy; no ABCC9/CMD1O-specific code was verified.

Open Targets maps MONDO:0012062 to ABCC9, but database association is not equivalent to definitive clinical validity. (OpenTargets Search: Dilated cardiomyopathy 1O)

Provenance

The disease entry derives from aggregated disease-level resources plus published research subjects, not longitudinal EHR-derived characterization. The defining human evidence comprises two index cases and one clinically affected father; recent statistics cited below concern DCM generally and must not be interpreted as CMD1O-specific. (bienengraeber2004abcc9mutationsidentified pages 2-2, bienengraeber2004abcc9mutationsidentified pages 1-2)

2. Etiology

Causal assertion and genetic risk

The historical causal assertion is heterozygous ABCC9 dysfunction affecting SUR2A-dependent cardiac KATP channels. In the original screen of 323 affected individuals, two exon-38 variants were found:

1. c.4537G>A, p.Ala1513Thr (reported originally as A1513T).
2. c.4570_4572delTTAinsAAAT, producing a frameshift beginning at Leu1524, four abnormal terminal residues, and premature termination (reported as Fs1524; exact modern protein HGVS should be transcript-validated).

Neither occurred among 500 unrelated controls. Both were germline heterozygous variants. The affected woman’s father also had severe DCM, supporting vertical transmission, but DNA-based segregation was unavailable; the affected man had no reported family history. (bienengraeber2004abcc9mutationsidentified pages 2-2, bienengraeber2004abcc9mutationsidentified pages 1-2, olson2010humankatpchannelopathies pages 5-6)

Interpretive qualification: the variants are historically described as disease mutations, but contemporary pathogenicity should be reassessed using the current MANE transcript, population frequency, ClinVar submissions, segregation, phenotype specificity, and ACMG/AMP criteria. The current gene–disease relationship is only Limited; a VUS in ABCC9 must not be used to diagnose CMD1O or predict disease in relatives. The 2024 review tabulated nine ClinVar P/LP entries but 712 VUS, illustrating the interpretive uncertainty. (micolonghi2024unveilingthespectrum pages 25-26)

Environmental and acquired risk factors

No environmental exposure has been demonstrated specifically in CMD1O. Mechanistically, impaired KATP metabolic sensing is expected to become consequential under increased energetic or hemodynamic demand. Related knockout models were relatively mild at baseline but developed calcium overload, arrhythmia, maladaptive remodeling, heart failure, and death during exercise, adrenergic stress, or experimental hypertension. Thus, hypertension and intense physiological stress are plausible “second hits,” but this remains inference rather than demonstrated CMD1O epidemiology. (kane2006kcnj11geneknockout pages 1-2, olson2010humankatpchannelopathies pages 5-6, kane2005cardiackatpchannels pages 10-10)

For DCM generally, relevant acquired contributors include alcohol, anthracyclines and other cardiotoxic therapies, pregnancy/peripartum stress, myocarditis, tachyarrhythmia, metabolic disease, and hypertension. These should be sought because finding an ABCC9 variant does not establish that it caused the phenotype. General DCM data also show adverse interaction with diabetes: in 1,152 nonischemic-DCM patients, 13% had type 2 diabetes; annual death/transplant events were 10.2% versus 5.7%, and adjusted risk was HR 1.61. (li2024theimpactof pages 1-2)

Protective factors

No protective ABCC9 allele is established for CMD1O. Reasonable environmental protection is extrapolated from DCM/HF care: blood-pressure control, avoidance of cardiotoxins and heavy alcohol, treatment of diabetes and sleep-disordered breathing, vaccination and prompt infection care where appropriate, moderate prescribed exercise rather than unassessed high-intensity exertion, and early treatment of ventricular dysfunction. These reduce general cardiac stress but have not been tested specifically in CMD1O.

3. Phenotypes

The tiny disease-specific sample precludes valid percentages. Frequencies should be recorded as observed in the original cases, not as population estimates.

The male was diagnosed at 55 and died of HF at 60. The female was diagnosed at 40; her father was diagnosed at 54 and died at 55. This supports adult onset with severe expression, but does not exclude preclinical disease or other ages of onset. Quality-of-life effects were not measured with EQ-5D, SF-36, Kansas City Cardiomyopathy Questionnaire, or another instrument; severe HFrEF and ventricular tachycardia would nevertheless be expected to impair exertion, employment, driving, and psychosocial well-being. (bienengraeber2004abcc9mutationsidentified pages 2-2, bienengraeber2004abcc9mutationsidentified pages 1-2)

Neurologic, myopathic, and white-matter phenotypes belong principally to biallelic ABCC9-related intellectual disability and myopathy syndrome (AIMS), not classical heterozygous CMD1O. A 2024 Brain study added nine individuals from seven families with homozygous loss-of-function variants; heterozygous parents generally lacked a conserved phenotype. AIMS should not be conflated with CMD1O, although occasional older heterozygotes had cardiac disease. DOI 10.1093/brain/awae010, published January 2024. (efthymiou2024novellossoffunctionvariants pages 2-4, efthymiou2024novellossoffunctionvariants pages 8-9)

4. Genetic and molecular information

Gene/protein

• Gene: ABCC9, ATP-binding cassette subfamily C member 9.
• Protein: sulfonylurea receptor 2 (SUR2); cardiac alternative terminal exon usage generates SUR2A.
• Cardiac channel: hetero-octameric KATP complex comprising four SUR2A regulatory subunits and four Kir6.2 pore subunits encoded by KCNJ11.
• Cellular location: predominantly cardiomyocyte sarcolemma/plasma membrane; SUR2-containing channels also occur in vascular smooth muscle, creating tissue-specific effects.

Variant consequences

Both original variants lie in evolutionarily conserved C-terminal sequence near the SUR2A catalytic ATPase pocket/Walker A region. Recombinant studies showed disturbed nucleotide-dependent conformational cycling and compromised metabolic-signal decoding. Reduced surface expression was reported, although pore conduction itself remained possible; the key defect was regulatory/catalytic gating rather than a simple absence of potassium permeability. (bienengraeber2004abcc9mutationsidentified pages 2-2, bienengraeber2004abcc9mutationsidentified pages 1-2)

The proposed effect is best described as disruptive/loss-of-regulatory function. A dominant-negative mechanism was not conclusively demonstrated. Population allele frequencies were not supplied beyond absence in 500 historical controls; current gnomAD frequencies should be checked against a transcript-normalized HGVS representation before clinical interpretation.

Related ABCC9 allelic disorders

• Biallelic loss of function: AIMS, with developmental impairment, myopathy/fatigability, CNS abnormalities, and sometimes cardiac systolic dysfunction. The 2024 study functionally confirmed nonfunctional channels for severe truncating/splice variants. (efthymiou2024novellossoffunctionvariants pages 2-4, efthymiou2024novellossoffunctionvariants pages 8-9)
• Heterozygous gain of function: Cantú syndrome, characterized by hypertrichosis, vascular dilation, hypotension, and cardiomegaly; this is mechanistically opposite to proposed CMD1O loss of metabolic gating. (nichols2023personalizedtherapeuticsfor pages 4-6)

No validated CMD1O-specific modifier gene, protective allele, recurrent chromosomal abnormality, germline-mosaicism series, or epigenetic signature was identified. No evidence supports a somatic origin.

5. Environmental information

There is no CMD1O-specific toxin, infectious agent, occupational exposure, diet, or lifestyle association. The practical etiologic work-up should nevertheless assess alcohol, cocaine or stimulants, cardiotoxic chemotherapy, immune-checkpoint inhibitors, pregnancy, endocrine and nutritional abnormalities, sustained tachycardia, hypertension, and myocarditis. Viral infection can trigger myocarditis and a DCM phenotype, but no pathogen is intrinsic to CMD1O.

The most defensible gene–environment model is that defective KATP metabolic–electrical coupling lowers myocardial stress tolerance, while hemodynamic, ischemic, adrenergic, or metabolic stress supplies the second hit. This is strongly supported in related channel-deficient animals but remains inferred for the two human CMD1O variants. (kane2006kcnj11geneknockout pages 1-2, kane2005cardiackatpchannels pages 10-10)

6. Mechanism and pathophysiology

Ordered causal chain

1. A heterozygous C-terminal ABCC9 variant leads to altered SUR2A abundance and/or ATPase-domain conformational cycling.
2. Altered SUR2A catalysis results in defective Mg-nucleotide-dependent regulation of the Kir6.2 potassium pore and impaired decoding of the ATP/ADP state. (bienengraeber2004abcc9mutationsidentified pages 2-2, olson2010humankatpchannelopathies pages 5-6)
3. Impaired KATP gating leads to failure to adapt action-potential duration and contractile work to energetic demand, particularly during adrenergic, ischemic, exercise, or pressure stress; this human step is mechanistically supported but partly inferred. (kane2006kcnj11geneknockout pages 1-2, olson2010humankatpchannelopathies pages 5-6)
4. Failed metabolic–electrical adaptation results in excessive calcium entry/overload and electrical instability; related KCNJ11-null mice demonstrate a calcium/calcineurin-dependent, cyclosporine-sensitive pathway. Extrapolation to ABCC9-CMD1O is indirect. (kane2006kcnj11geneknockout pages 1-2)
5. Calcium dysregulation and repeated energetic stress lead to two branches:
6. Electrical branch: abnormal repolarization and triggered/re-entrant activity result in ventricular tachycardia and risk of sudden death.
7. Mechanical branch: cardiomyocyte injury and maladaptive remodeling result in chamber dilatation, declining contractility, HFrEF, and secondary fibrosis.
8. Progressive low-output and congestive physiology leads to exercise intolerance, neurohormonal activation, pulmonary/systemic congestion, advanced HF, transplantation, or death.

Processes, pathways, and ontology suggestions

• Upstream: ATP/ADP sensing, ATP hydrolysis, KATP-channel gating, potassium transport, membrane repolarization.
• Intermediate: cardiac action-potential regulation, excitation–contraction coupling, calcium-ion homeostasis, calcineurin signaling, energetic adaptation.
• Downstream: cardiomyocyte injury, hypertrophic/remodeling response, fibrosis, chamber dilation, systolic dysfunction, arrhythmogenesis.
• Suggested GO biological processes: ATP-sensitive potassium-channel activity/regulation; potassium-ion transmembrane transport; regulation of membrane potential; cardiac action-potential regulation; cellular response to hypoxia; calcium-ion homeostasis; cardiac muscle contraction; regulation of heart growth; response to mechanical stimulus.
• Suggested GO cellular components: plasma membrane; sarcolemma; ATP-sensitive potassium-channel complex; nucleotide-binding domain.
• Suggested Cell Ontology terms: cardiac muscle cell/cardiomyocyte; ventricular cardiac muscle cell; vascular smooth-muscle cell; cardiac fibroblast (downstream remodeling); endothelial cell.

Conflicting/context-dependent findings

Complete or tissue-selective SUR2 loss is not uniformly harmful. Adult cardiomyocyte-specific deletion in mice increased glucose uptake, shifted metabolism toward glycolysis, and protected against ischemia–reperfusion injury. Global deletion also affects vascular KATP channels and can cause hypertension, coronary vasospasm, bradycardia, and sudden death, potentially producing chronic preconditioning. These findings show that developmental timing, cell type, stressor, isoform, and degree of channel dysfunction matter; they weaken any simplistic claim that all ABCC9 loss directly causes DCM. (aubert2019deletionofsulfonylurea pages 1-2)

No CMD1O-specific human myocardial transcriptomic, proteomic, metabolomic, lipidomic, methylomic, single-cell, spatial-transcriptomic, CRISPR-screen, or multi-omic study was found. Related KATP-deficient-heart proteomics cannot be treated as a CMD1O molecular signature.

7. Anatomical structures affected

• Primary organ/system: heart/cardiovascular system.
• Primary chamber: left ventricle; biventricular involvement is possible in DCM generally but was not characterized in the original cases.
• Tissue: myocardium/cardiac muscle tissue.
• Primary cell: ventricular cardiomyocyte.
• Secondary structures: atria, conduction system, and ventricular electrical substrate; lungs, liver, kidneys, and peripheral tissues can be affected secondarily through congestion or low output.
• Subcellular localization: cardiomyocyte sarcolemma, KATP-channel complex, cytosol-facing nucleotide-binding domains; downstream calcium-handling machinery and mitochondria are functionally implicated but not shown as primary ABCC9 lesion sites.
• Suggested UBERON concepts: heart (UBERON:0000948), myocardium, left ventricle (UBERON:0002084), cardiac muscle tissue, cardiac conduction system.
• Lateralization: not applicable; the disease is not unilateral, although left-ventricular involvement predominates.

8. Temporal development

The observed onset was insidious adult onset at 40–55 years. The course was chronic and progressive: severe dilation and systolic dysfunction were present at diagnosis, and two affected men died from HF within one to five years. There are insufficient data to define presymptomatic, early, intermediate, or genotype-specific progression rates. (bienengraeber2004abcc9mutationsidentified pages 2-2)

A practical staged model extrapolated from DCM is: genotype-positive/phenotype-negative; subtle ECG, strain, dilation, or scar abnormality; overt DCM/HFrEF; ventricular arrhythmia or decompensated HF; and end-stage HF. CMR and strain imaging may detect intermediate disease, while ECG and echocardiography remain central to serial screening. (sorella2025diagnosisandmanagement pages 2-3, gigli2025pathophysiologyofdilated pages 4-6)

Recovery is possible in DCM generally but is not documented for CMD1O. In a 2025 Japanese first-onset DCM cohort, 82/121 patients (68%) achieved LVEF ≥40% with ≥10-point improvement at a median 208 days; the rate was 89.5% in 2018–2022 versus 48.4% in 2007–2017. These treatment-era figures are not genotype-specific and should not be used as CMD1O penetrance or recovery estimates. (wanezaki2025recenttrendsin pages 1-2)

9. Inheritance and population

Inheritance

The asserted CMD1O model is autosomal dominant, based mainly on heterozygous variants and father–daughter disease in one family. Penetrance is unknown and likely age- and stress-dependent if the association is genuine. Expressivity appears variable, but the sample is too small for inference. No anticipation, founder effect, consanguinity contribution, carrier frequency, or germline mosaicism has been established. (bienengraeber2004abcc9mutationsidentified pages 2-2, micolonghi2024unveilingthespectrum pages 25-26)

This is distinct from autosomal-recessive AIMS, in which affected individuals carry biallelic ABCC9 loss-of-function variants and heterozygous parents are generally unaffected. (efthymiou2024novellossoffunctionvariants pages 2-4, efthymiou2024novellossoffunctionvariants pages 8-9)

Epidemiology

There is no CMD1O-specific prevalence, incidence, sex ratio, geographic distribution, or ancestry estimate. Two variants among 323 selected DCM cases must not be converted into population prevalence.

General contemporary DCM estimates provide context only. Recent analyses estimate prevalence around 1 in 220–250, although methodology produces values from approximately 59 to 280 per 100,000 and incidence around 3.6–7 per 100,000 person-years. (cheema2025trendsanddisparities pages 1-2, ramoslopez2026epidemiologyofnonischaemic pages 3-5)

A 2025 meta-analysis of 99 studies and 37,525 participants found a female proportion of 0.30 and male:female ratio of 2.38:1; genetically identified DCM remained male-predominant at 2.22:1. Sex-specific imaging reduced the apparent disparity, suggesting both biological penetrance differences and underdiagnosis in women. These data are general DCM, not ABCC9-specific. DOI 10.1161/CIRCULATIONAHA.124.070872, February 2025. (bergan2025systematicreviewmetaanalysis pages 1-2)

10. Diagnostics

Clinical diagnostic approach

1. Confirm the phenotype: history, examination, three-to-four-generation pedigree, 12-lead ECG, ambulatory rhythm monitoring, transthoracic echocardiography, and CMR.
2. Measure severity/complications: BNP or NT-proBNP, high-sensitivity troponin, renal function, electrolytes, liver profile, blood count, thyroid function, iron studies, and other phenotype-directed tests.
3. Exclude mimics/secondary causes: ischemic heart disease, hypertension/loading disease, valve or congenital disease, myocarditis, alcohol/toxins, tachycardia-mediated dysfunction, endocrine/metabolic disease, neuromuscular disease, and pregnancy-related disease.
4. Characterize tissue: CMR for volumes, function, edema and late gadolinium enhancement. Endomyocardial biopsy is reserved for selected cases in which noninvasive testing fails and a biopsy-defined diagnosis would alter treatment. (sorella2025diagnosisandmanagement pages 2-3)
5. Assess arrhythmia: ECG, Holter/patch monitoring, exercise testing when safe, and electrophysiology evaluation when indicated.

Current guideline synthesis identifies consensus for BNP/troponin, multimodality imaging, genetic counseling, and advanced-HF management. (sorella2025diagnosisandmanagement pages 1-2, sorella2025diagnosisandmanagement pages 2-3)

Genetic testing

Use a phenotype-focused, evidence-curated cardiomyopathy/arrhythmia panel rather than ABCC9-only testing. Sequence and deletion/duplication analysis of high-evidence DCM genes should be prioritized. ABCC9 may be included as a Limited-evidence gene, but interpretation must be conservative. WES or WGS is reasonable after a negative panel when syndromic features, atypical inheritance, structural variation, or a strong family history remains unexplained. WGS may detect noncoding and structural variants, but clinical interpretation—not sequencing capacity—is the limiting step.

CMA, karyotyping, FISH, mitochondrial DNA testing, and repeat-expansion assays are not routine for isolated CMD1O; use them only when the phenotype suggests a chromosomal, mitochondrial, or repeat disorder. RNA sequencing can clarify suspected splice variants where relevant tissue or validated surrogate cells are available, but it is not an established CMD1O diagnostic.

A pathogenic/likely pathogenic familial variant should prompt counseling and targeted cascade testing. Genotype-positive relatives require longitudinal ECG and imaging; phenotype-negative relatives who test negative for a convincingly causal familial variant can generally be discharged from variant-specific surveillance. An ABCC9 VUS must not drive cascade predictive testing. (sorella2025diagnosisandmanagement pages 12-13, gigli2025pathophysiologyofdilated pages 4-6, micolonghi2024unveilingthespectrum pages 25-26)

Differential diagnosis

Key alternatives include TTN-, LMNA-, FLNC-, DSP-, RBM20-, PLN-, BAG3-, SCN5A-, and sarcomeric DCM; arrhythmogenic cardiomyopathy; myocarditis; ischemic, alcoholic, chemotherapy-related, peripartum, tachycardia-induced, mitochondrial, and neuromuscular cardiomyopathies; cardiac sarcoidosis; hemochromatosis; and Fabry disease. Distinguishing evidence comes from pedigree, extracardiac findings, variant validity, coronary assessment, CMR scar distribution, inflammation, and targeted laboratory/biopsy findings.

11. Outcome and prognosis

CMD1O-specific survival curves do not exist. Two severe deaths—at 55 and 60 years—are subject to profound ascertainment bias and cannot establish life expectancy. Ventricular tachycardia, very low LVEF, advanced HF, and family history of sudden death are clinically adverse features. (bienengraeber2004abcc9mutationsidentified pages 2-2)

General DCM prognostic evidence includes:

• In 1,272 DCM patients with LVEF ≤35%, LGE ≥7.5% predicted SCD/aborted SCD with adjusted HR 4.11; combining LGE ≥7.5% with LVEF ≤20% gave a 7.12-fold risk and 4.8% annual event rate. (zhou2025prognosisandrisk pages 1-2)
• In the United States, 184,073 DCM-associated deaths occurred during 1999–2023; age-adjusted mortality fell from 5.19 to 2.34 per 100,000. In 2023 it was 3.4 in men and 1.38 in women. These are death-certificate data for all DCM, not CMD1O. (cheema2025trendsanddisparities pages 1-2)
• Reverse remodeling predicts a better course, but recovery is remission rather than proof of cure; continued surveillance is appropriate in genetic or arrhythmic disease.

Potential complications include progressive HFrEF, ventricular tachycardia/fibrillation, sudden cardiac death, atrial arrhythmia, functional mitral regurgitation, intracardiac thrombus and embolism, pulmonary hypertension, renal/hepatic dysfunction, hospitalization, LVAD, and transplantation.

12. Treatment

No treatment has been validated specifically for ABCC9-CMD1O. Management follows DCM/HFrEF and ventricular-arrhythmia guidelines.

Pharmacotherapy

• ARNI (sacubitril/valsartan), or ACE inhibitor/ARB when ARNI is unsuitable.
• Evidence-based beta-blocker.
• Mineralocorticoid-receptor antagonist.
• SGLT2 inhibitor, regardless of diabetes status.
• Loop diuretic for congestion; add a thiazide-type agent selectively for resistant edema.
• Consider ivabradine, hydralazine/isosorbide dinitrate, digoxin, or vericiguat according to rhythm, blood pressure, renal function, symptoms, and guideline indications.

The four foundational classes should generally be introduced promptly at tolerated doses rather than waiting to maximize one before starting the next. In DAPA-HF and EMPEROR-Reduced, SGLT2 inhibitors reduced primary endpoints by 26% and 25%, respectively; these are HFrEF trial data, not CMD1O-specific results. (badger2023summaryandcomparison pages 9-11, badger2023summaryandcomparison pages 11-12)

Anticoagulation is not routine solely for DCM; use it for atrial fibrillation according to thromboembolic risk, documented LV thrombus, prior embolism, or another standard indication.

Devices and advanced care

• ICD: secondary prevention after malignant ventricular arrhythmia/cardiac arrest; primary prevention after optimized therapy according to LVEF, symptoms, scar, genotype and individualized competing-risk assessment.
• CRT: strongest conventional indication is symptomatic HF, LVEF ≤35%, sinus rhythm, left-bundle-branch block, and QRS ≥150 ms; benefit is less certain with narrower QRS or non-LBBB morphology. (badger2023summaryandcomparison pages 11-12)
• Catheter ablation: for recurrent ventricular tachycardia when indicated.
• LVAD/MCS and transplantation: for advanced NYHA III–IV HF refractory to medical and device therapy. MCS may bridge to transplantation or serve as selected destination therapy. (sorella2025diagnosisandmanagement pages 12-13)

Targeted and experimental therapy

KATP openers or inhibitors are not established CMD1O therapy. Available modulators can affect pancreatic, vascular, skeletal-muscle, and cardiac channel combinations differently; the context-dependent mouse results make empiric channel manipulation unsafe outside research. Preclinical glibenclamide work largely concerns gain-of-function Cantú syndrome, not CMD1O. No ABCC9-directed gene therapy, ASO, RNA therapy, CRISPR treatment, or CMD1O-specific interventional trial was identified in the ClinicalTrials.gov search. (aubert2019deletionofsulfonylurea pages 1-2, nichols2023personalizedtherapeuticsfor pages 4-6)

Suggested NCIt intervention mappings include angiotensin-receptor neprilysin inhibitor therapy, beta-adrenergic blocking-agent therapy, mineralocorticoid-receptor antagonist therapy, SGLT2-inhibitor therapy, diuretic therapy, implantable cardioverter-defibrillator placement, cardiac-resynchronization therapy, ventricular-assist-device placement, catheter ablation, and heart transplantation.

13. Prevention

Primary prevention

The genetic lesion itself cannot currently be prevented after conception. At-risk families should receive genetic counseling, but reproductive decisions require explicit discussion that the ABCC9–DCM relationship is Limited. Where a familial variant is independently classified as pathogenic/likely pathogenic with persuasive segregation, prenatal diagnosis or preimplantation genetic testing may be technically possible; it should not be offered for a VUS as though disease were certain.

Reduce modifiable myocardial stress: control hypertension and diabetes, avoid smoking and illicit stimulants, avoid heavy alcohol, review cardiotoxic drugs, maintain healthy weight, and use individualized exercise advice. Influenza, COVID-19, and pneumococcal vaccination are appropriate according to national HF guidance; no vaccine prevents CMD1O itself.

Secondary prevention

• Clinical screening of first-degree relatives with history, ECG and echocardiography; add CMR and rhythm monitoring when indicated.
• Targeted cascade testing only for a convincingly pathogenic familial variant.
• Repeat surveillance for genotype-positive/phenotype-negative relatives because penetrance may be age dependent. (sorella2025diagnosisandmanagement pages 12-13, gigli2025pathophysiologyofdilated pages 4-6)

Tertiary prevention

Optimize foundational HFrEF therapy, treat congestion, monitor electrolytes/renal function, manage arrhythmias, consider ICD/CRT, provide cardiac rehabilitation, and refer early for advanced-HF assessment. Regular moderate activity is encouraged in stable HF, whereas high-intensity competitive exercise requires individualized arrhythmic-risk assessment. (badger2023summaryandcomparison pages 9-11)

14. Other species and natural disease

No naturally occurring, breed-defined veterinary equivalent of human CMD1O was identified. Accordingly, no VBO breed term, animal prevalence, zoonotic potential, or cross-species transmission applies. CMD1O is noninfectious and not zoonotic.

Relevant orthologues include mouse Abcc9 (Mus musculus, NCBI Taxonomy 10090) and zebrafish abcc9 (Danio rerio, Taxonomy 7955). Conservation of SUR2-containing KATP channels supports comparative study, but experimentally engineered disease is not evidence of naturally occurring veterinary CMD1O.

15. Model organisms

Mouse

• SUR2/Abcc9 loss models show fatigability and cardiac dysfunction, supporting a role in muscle and myocardial physiology. Global models are complicated by vascular dysfunction, hypertension, coronary vasospasm, bradycardia, and sudden death. (smeland2019abcc9relatedintellectualdisability pages 1-2)
• Related Kcnj11/Kir6.2-null mice are informative for channel-complex failure: baseline findings may be mild, whereas exercise or hypertension produces calcium overload, arrhythmia, calcineurin-dependent remodeling, HF, and death. This is pathway-level, not variant-specific, evidence. (kane2006kcnj11geneknockout pages 1-2)
• Adult cardiomyocyte-specific SUR2 deletion can instead enhance glucose uptake and protect against ischemia–reperfusion injury, demonstrating model and stress dependence. (aubert2019deletionofsulfonylurea pages 1-2)

Zebrafish

Abcc9 loss causes reduced activity, ventricular enlargement, and cardiac dysfunction; zebrafish cardiomyocytes and vascular smooth muscle possess broadly comparable KATP-channel composition and metabolic sensitivity. However, fish channels respond differently to some openers such as pinacidil and minoxidil, limiting pharmacologic translation. (smeland2019abcc9relatedintellectualdisability pages 1-2)

Cellular systems

HEK293/recombinant-channel assays co-expressing SUR2A variants with Kir6.2 demonstrated abnormal gating or complete loss of current for severe loss-of-function alleles. Such systems provide strong molecular-function evidence but lack myocardial architecture, neurohormonal signaling, developmental context, vascular effects, and chronic loading.

No published patient-specific iPSC-cardiomyocyte, engineered-heart-tissue, cardiac-organoid, or knock-in model of p.Ala1513Thr/Fs1524 was identified. Such models, combined with isogenic correction and mechanical/metabolic stress, would be especially valuable for resolving the Limited gene–disease validity.

Evidence-based knowledge-base conclusion

CMD1O should be entered with MONDO:0012062, OMIM 608569, and candidate causal gene ABCC9, but with a prominent Limited clinical-validity flag. The best-supported phenotype is severe adult-onset DCM with ventricular tachycardia; the best-supported mechanism is disruption of SUR2A-dependent KATP metabolic gating. Yet the human evidence consists essentially of two historical index variants, limited segregation, and no disease-specific natural-history cohort. Current diagnosis and treatment should therefore be phenotype driven, should investigate stronger DCM genes and acquired causes, and should not treat an ABCC9 VUS as diagnostic. Recent AIMS studies strengthen the biological importance of ABCC9 loss but establish a distinct recessive multisystem disorder rather than independently proving dominant CMD1O. (efthymiou2024novellossoffunctionvariants pages 2-4, micolonghi2024unveilingthespectrum pages 25-26, micolonghi2024unveilingthespectrum pages 8-9)

Key dated sources

1. Bienengraeber M, et al. “ABCC9 mutations identified in human dilated cardiomyopathy disrupt catalytic KATP channel gating.” Nature Genetics. Online 21 March 2004; issue April 2004. PMID 15034580. https://doi.org/10.1038/ng1329. (bienengraeber2004abcc9mutationsidentified pages 2-2)
2. Olson TM, Terzic A. “Human KATP channelopathies: diseases of metabolic homeostasis.” Pflügers Archiv. 2010. https://doi.org/10.1007/s00424-009-0771-y. (olson2010humankatpchannelopathies pages 5-6)
3. Jordan E, et al. “Evidence-Based Assessment of Genes in Dilated Cardiomyopathy.” Circulation. 2021;144:7–19. PMID 33947203. https://doi.org/10.1161/CIRCULATIONAHA.120.053033. This expert curation supports caution with low-evidence DCM genes.
4. Efthymiou S, et al. “Novel loss-of-function variants expand ABCC9-related intellectual disability and myopathy syndrome.” Brain. Published January 2024;147:1822–1836. https://doi.org/10.1093/brain/awae010. (efthymiou2024novellossoffunctionvariants pages 2-4)
5. Micolonghi C, et al. “Unveiling the Spectrum of Minor Genes in Cardiomyopathies.” International Journal of Molecular Sciences. 11 September 2024. https://doi.org/10.3390/ijms25189787. Reports ABCC9–DCM as ClinGen Limited. (micolonghi2024unveilingthespectrum pages 25-26)
6. Sorella A, et al. “Diagnosis and management of dilated cardiomyopathy.” Accepted 13 December and online 14 December 2024; European Heart Journal—Quality of Care & Clinical Outcomes 2025. https://doi.org/10.1093/ehjqcco/qcae109. (sorella2025diagnosisandmanagement pages 1-2, sorella2025diagnosisandmanagement pages 2-3)
7. Li Y, et al. Nonischemic DCM and diabetes prospective cohort. Cardiovascular Diabetology. February 2024. https://doi.org/10.1186/s12933-024-02134-0. (li2024theimpactof pages 1-2)
8. Bergan N, et al. DCM sex-ratio meta-analysis. Circulation. February 2025. https://doi.org/10.1161/CIRCULATIONAHA.124.070872. (bergan2025systematicreviewmetaanalysis pages 1-2)

References

1. (bienengraeber2004abcc9mutationsidentified pages 2-2): Martin Bienengraeber, Timothy M Olson, Vitaliy A Selivanov, Eva C Kathmann, Fearghas O'Cochlain, Fan Gao, Amy B Karger, Jeffrey D Ballew, Denice M Hodgson, Leonid V Zingman, Yuan-Ping Pang, Alexey E Alekseev, and Andre Terzic. Abcc9 mutations identified in human dilated cardiomyopathy disrupt catalytic katp channel gating. Nature Genetics, 36:382-387, Apr 2004. URL: https://doi.org/10.1038/ng1329, doi:10.1038/ng1329. This article has 506 citations and is from a highest quality peer-reviewed journal.

2. (micolonghi2024unveilingthespectrum pages 25-26): Caterina Micolonghi, Federica Perrone, Marco Fabiani, Silvia Caroselli, Camilla Savio, Antonio Pizzuti, Aldo Germani, Vincenzo Visco, Simona Petrucci, Speranza Rubattu, and Maria Piane. Unveiling the spectrum of minor genes in cardiomyopathies: a narrative review. Sep 2024. URL: https://doi.org/10.3390/ijms25189787, doi:10.3390/ijms25189787. This article has 11 citations.

3. (micolonghi2024unveilingthespectrum pages 8-9): Caterina Micolonghi, Federica Perrone, Marco Fabiani, Silvia Caroselli, Camilla Savio, Antonio Pizzuti, Aldo Germani, Vincenzo Visco, Simona Petrucci, Speranza Rubattu, and Maria Piane. Unveiling the spectrum of minor genes in cardiomyopathies: a narrative review. Sep 2024. URL: https://doi.org/10.3390/ijms25189787, doi:10.3390/ijms25189787. This article has 11 citations.

4. (bienengraeber2004abcc9mutationsidentified pages 1-2): Martin Bienengraeber, Timothy M Olson, Vitaliy A Selivanov, Eva C Kathmann, Fearghas O'Cochlain, Fan Gao, Amy B Karger, Jeffrey D Ballew, Denice M Hodgson, Leonid V Zingman, Yuan-Ping Pang, Alexey E Alekseev, and Andre Terzic. Abcc9 mutations identified in human dilated cardiomyopathy disrupt catalytic katp channel gating. Nature Genetics, 36:382-387, Apr 2004. URL: https://doi.org/10.1038/ng1329, doi:10.1038/ng1329. This article has 506 citations and is from a highest quality peer-reviewed journal.

5. (OpenTargets Search: Dilated cardiomyopathy 1O): Open Targets Query (Dilated cardiomyopathy 1O, 3 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.

6. (olson2010humankatpchannelopathies pages 5-6): Timothy M. Olson and Andre Terzic. Human katp channelopathies: diseases of metabolic homeostasis. Pflugers Archiv, 460:295-306, Dec 2010. URL: https://doi.org/10.1007/s00424-009-0771-y, doi:10.1007/s00424-009-0771-y. This article has 155 citations.

7. (kane2006kcnj11geneknockout pages 1-2): Garvan C. Kane, Atta Behfar, Roy B. Dyer, D. Fearghas O'Cochlain, Xiao-Ke Liu, Denice M. Hodgson, Santiago Reyes, Takashi Miki, Susumu Seino, and Andre Terzic. Kcnj11 gene knockout of the kir6.2 katp channel causes maladaptive remodeling and heart failure in hypertension. Human molecular genetics, 15 15:2285-97, Aug 2006. URL: https://doi.org/10.1093/hmg/ddl154, doi:10.1093/hmg/ddl154. This article has 134 citations and is from a domain leading peer-reviewed journal.

8. (smeland2019abcc9relatedintellectualdisability pages 1-2): Marie F. Smeland, Conor McClenaghan, Helen I. Roessler, Sanne Savelberg, Geir Åsmund Myge Hansen, Helene Hjellnes, Kjell Arne Arntzen, Kai Ivar Müller, Andreas Rosenberger Dybesland, Theresa Harter, Monica Sala-Rabanal, Chris H. Emfinger, Yan Huang, Soma S. Singareddy, Jamie Gunn, David F. Wozniak, Attila Kovacs, Maarten Massink, Federico Tessadori, Sarah M. Kamel, Jeroen Bakkers, Maria S. Remedi, Marijke Van Ghelue, Colin G. Nichols, and Gijs van Haaften. Abcc9-related intellectual disability myopathy syndrome is a katp channelopathy with loss-of-function mutations in abcc9. Nature Communications, Oct 2019. URL: https://doi.org/10.1038/s41467-019-12428-7, doi:10.1038/s41467-019-12428-7. This article has 56 citations and is from a highest quality peer-reviewed journal.

9. (kane2005cardiackatpchannels pages 10-10): G. Kane, Xiao‐Ke Liu, S. Yamada, T. Olson, and A. Terzic. Cardiac katp channels in health and disease. Journal of molecular and cellular cardiology, 38 6:937-43, Jun 2005. URL: https://doi.org/10.1016/j.yjmcc.2005.02.026, doi:10.1016/j.yjmcc.2005.02.026. This article has 260 citations and is from a domain leading peer-reviewed journal.

10. (aubert2019deletionofsulfonylurea pages 1-2): Gregory Aubert, David Y. Barefield, Alexis R. Demonbreun, Mohun Ramratnam, Katherine S. Fallon, James L. Warner, Ann E. Rossi, Michele Hadhazy, Jonathan C. Makielski, and Elizabeth M. McNally. Deletion of sulfonylurea receptor 2 in the adult myocardium enhances cardiac glucose uptake and is cardioprotective. JACC: Basic to Translational Science, 4:251-268, Apr 2019. URL: https://doi.org/10.1016/j.jacbts.2018.11.012, doi:10.1016/j.jacbts.2018.11.012. This article has 11 citations.

11. (sorella2025diagnosisandmanagement pages 2-3): Anna Sorella, Kristian Galanti, Lorena Iezzi, Sabina Gallina, Selma F Mohammed, Neha Sekhri, Mohammed Majid Akhtar, Sanjay K Prasad, Choudhary Anwar Ahmed Chahal, Fabrizio Ricci, and Mohammed Yunus Khanji. Diagnosis and management of dilated cardiomyopathy: a systematic review of clinical practice guidelines and recommendations. European Heart Journal. Quality of Care & Clinical Outcomes, 11:206-222, Dec 2025. URL: https://doi.org/10.1093/ehjqcco/qcae109, doi:10.1093/ehjqcco/qcae109. This article has 45 citations.

12. (sorella2025diagnosisandmanagement pages 12-13): Anna Sorella, Kristian Galanti, Lorena Iezzi, Sabina Gallina, Selma F Mohammed, Neha Sekhri, Mohammed Majid Akhtar, Sanjay K Prasad, Choudhary Anwar Ahmed Chahal, Fabrizio Ricci, and Mohammed Yunus Khanji. Diagnosis and management of dilated cardiomyopathy: a systematic review of clinical practice guidelines and recommendations. European Heart Journal. Quality of Care & Clinical Outcomes, 11:206-222, Dec 2025. URL: https://doi.org/10.1093/ehjqcco/qcae109, doi:10.1093/ehjqcco/qcae109. This article has 45 citations.

13. (badger2023summaryandcomparison pages 9-11): Sarah Badger, James McVeigh, and Praveen Indraratna. Summary and comparison of the 2022 acc/aha/hfsa and 2021 esc heart failure guidelines. Cardiology and Therapy, 12:571-588, Aug 2023. URL: https://doi.org/10.1007/s40119-023-00328-3, doi:10.1007/s40119-023-00328-3. This article has 12 citations and is from a peer-reviewed journal.

14. (badger2023summaryandcomparison pages 11-12): Sarah Badger, James McVeigh, and Praveen Indraratna. Summary and comparison of the 2022 acc/aha/hfsa and 2021 esc heart failure guidelines. Cardiology and Therapy, 12:571-588, Aug 2023. URL: https://doi.org/10.1007/s40119-023-00328-3, doi:10.1007/s40119-023-00328-3. This article has 12 citations and is from a peer-reviewed journal.

15. (nichols2023personalizedtherapeuticsfor pages 4-6): Colin G. Nichols. Personalized therapeutics for k_atp-dependent pathologies. Jan 2023. URL: https://doi.org/10.1146/annurev-pharmtox-051921-123023, doi:10.1146/annurev-pharmtox-051921-123023. This article has 31 citations and is from a highest quality peer-reviewed journal.

16. (sorella2025diagnosisandmanagement pages 1-2): Anna Sorella, Kristian Galanti, Lorena Iezzi, Sabina Gallina, Selma F Mohammed, Neha Sekhri, Mohammed Majid Akhtar, Sanjay K Prasad, Choudhary Anwar Ahmed Chahal, Fabrizio Ricci, and Mohammed Yunus Khanji. Diagnosis and management of dilated cardiomyopathy: a systematic review of clinical practice guidelines and recommendations. European Heart Journal. Quality of Care & Clinical Outcomes, 11:206-222, Dec 2025. URL: https://doi.org/10.1093/ehjqcco/qcae109, doi:10.1093/ehjqcco/qcae109. This article has 45 citations.

17. (li2024theimpactof pages 1-2): Yangjie Li, Hong Xian, Yuanwei Xu, Weihao Li, Jiajun Guo, Ke Wan, Jie Wang, Ziqian Xu, Qing Zhang, Yuchi Han, Jiayu Sun, and Yucheng Chen. The impact of type 2 diabetes mellitus on the clinical profile, myocardial fibrosis, and prognosis in non-ischemic dilated cardiomyopathy: a prospective cohort study. Cardiovascular Diabetology, Feb 2024. URL: https://doi.org/10.1186/s12933-024-02134-0, doi:10.1186/s12933-024-02134-0. This article has 16 citations and is from a peer-reviewed journal.

18. (efthymiou2024novellossoffunctionvariants pages 2-4): Stephanie Efthymiou, Marcello Scala, Vini Nagaraj, Katarzyna Ochenkowska, Fenne L Komdeur, Robin A Liang, Mohamed S Abdel-Hamid, Tipu Sultan, Tuva Barøy, Marijke Van Ghelue, Barbara Vona, Reza Maroofian, Faisal Zafar, Fowzan S Alkuraya, Maha S Zaki, Mariasavina Severino, Kingsley C Duru, Robert C Tryon, Lin Vigdis Brauteset, Morad Ansari, Mark Hamilton, Mieke M van Haelst, Gijs van Haaften, Federico Zara, Henry Houlden, Éric Samarut, Colin G Nichols, Marie F Smeland, and Conor McClenaghan. Novel loss-of-function variants expand abcc9-related intellectual disability and myopathy syndrome. Brain, 147:1822-1836, Jan 2024. URL: https://doi.org/10.1093/brain/awae010, doi:10.1093/brain/awae010. This article has 18 citations and is from a highest quality peer-reviewed journal.

19. (efthymiou2024novellossoffunctionvariants pages 8-9): Stephanie Efthymiou, Marcello Scala, Vini Nagaraj, Katarzyna Ochenkowska, Fenne L Komdeur, Robin A Liang, Mohamed S Abdel-Hamid, Tipu Sultan, Tuva Barøy, Marijke Van Ghelue, Barbara Vona, Reza Maroofian, Faisal Zafar, Fowzan S Alkuraya, Maha S Zaki, Mariasavina Severino, Kingsley C Duru, Robert C Tryon, Lin Vigdis Brauteset, Morad Ansari, Mark Hamilton, Mieke M van Haelst, Gijs van Haaften, Federico Zara, Henry Houlden, Éric Samarut, Colin G Nichols, Marie F Smeland, and Conor McClenaghan. Novel loss-of-function variants expand abcc9-related intellectual disability and myopathy syndrome. Brain, 147:1822-1836, Jan 2024. URL: https://doi.org/10.1093/brain/awae010, doi:10.1093/brain/awae010. This article has 18 citations and is from a highest quality peer-reviewed journal.

20. (gigli2025pathophysiologyofdilated pages 4-6): Marta Gigli, Davide Stolfo, Marco Merlo, Gianfranco Sinagra, Matthew R. G. Taylor, and Luisa Mestroni. Pathophysiology of dilated cardiomyopathy: from mechanisms to precision medicine. Nature reviews. Cardiology, 22:183-198, Oct 2025. URL: https://doi.org/10.1038/s41569-024-01074-2, doi:10.1038/s41569-024-01074-2. This article has 98 citations.

21. (wanezaki2025recenttrendsin pages 1-2): Masahiro Wanezaki, Tetsu Watanabe, Atsushi Iizuka, Tomoki Kobayashi, Shunsuke Edamura, Takayuki Sugai, Harutoshi Tamura, Satoshi Nishiyama, Ryuhei Yamaguchi, Naoaki Hashimoto, Yoichiro Otaki, Daisuke Kutsuzawa, Shigehiko Kato, Takanori Arimoto, Shunsuke Inoue, Toshiyuki Ko, Seitaro Nomura, Issei Komuro, and Masafumi Watanabe. Recent trends in achievement rates and time required for left ventricular reverse remodeling in dilated cardiomyopathy. Feb 2025. URL: https://doi.org/10.1253/circrep.cr-24-0148, doi:10.1253/circrep.cr-24-0148. This article has 0 citations and is from a peer-reviewed journal.

22. (cheema2025trendsanddisparities pages 1-2): Zian Zafar Cheema, Mohammad Atout, Taha Kassim Dohadwala, Ahmed Talaat Deiab, Aya Abouayana, Hazim Mesmar, Asmaa Hasan, Amaad Alam Shah, Muhammad Babar Mahmood, Daniel James Lewis, Hasan Ahmed, Maryam Shahzad, Mushood Ahmed, Nabeel Ahmed, Raheel Ahmed, and Syed Khurram M. Gardezi. Trends and disparities in dilated cardiomyopathy related mortality among adults in the united states: a cdc wonder analysis (1999–2023). PLOS One, 20(10):e0333525, Oct 2025. URL: https://doi.org/10.1371/journal.pone.0333525, doi:10.1371/journal.pone.0333525. This article has 3 citations and is from a peer-reviewed journal.

23. (ramoslopez2026epidemiologyofnonischaemic pages 3-5): Noemí Ramos-López, Fernando Domínguez, Juan Pablo Ochoa, Enrique Lara-Pezzi, and Pablo Garcia-Pavia. Epidemiology of non-ischaemic dilated cardiomyopathy. Nature Reviews Cardiology, May 2026. URL: https://doi.org/10.1038/s41569-026-01300-z, doi:10.1038/s41569-026-01300-z. This article has 0 citations and is from a domain leading peer-reviewed journal.

24. (bergan2025systematicreviewmetaanalysis pages 1-2): Natalie Bergan, Ishika Prachee, Lara Curran, Kathryn A. McGurk, Chang Lu, Antonio de Marvao, Wenjia Bai, Brian P. Halliday, John Gregson, Declan P. O’Regan, James S. Ware, and Upasana Tayal. Systematic review, meta-analysis, and population study to determine the biologic sex ratio in dilated cardiomyopathy. Feb 2025. URL: https://doi.org/10.1161/circulationaha.124.070872, doi:10.1161/circulationaha.124.070872. This article has 21 citations and is from a highest quality peer-reviewed journal.

25. (zhou2025prognosisandrisk pages 1-2): Di Zhou, Leyi Zhu, Shuang Li, Weichun Wu, Baiyan Zhuang, Jing Xu, Wenjing Yang, Jian He, Yining Wang, Yuhui Zhang, Guanshu Liu, Xiaoxin Sun, Qiang Zhang, Zhongzhao Teng, Arlene Sirajuddin, Andrew E. Arai, Shihua Zhao, and Minjie Lu. Prognosis and risk stratification in dilated cardiomyopathy with lvef≤35%: cardiac mri insights for better outcomes. Circulation. Cardiovascular Imaging, 18:e017246-e017246, Mar 2025. URL: https://doi.org/10.1161/circimaging.124.017246, doi:10.1161/circimaging.124.017246. This article has 9 citations.

Artifacts

• Edison artifact artifact-00

Reference Validation

Checked with linkml-reference-validator 0.2.1.

All extracted references resolved successfully.

Term Validation

Checked with linkml-term-validator 0.4.5, through the ols: adapter.

Terms the report names something else

These identifiers resolve, so nothing about them looks wrong, and the ontology calls them something unrelated to what the report calls them. That usually means the identifier is not the one the sentence needs:

• UBERON:0000948 (1 mention) - the report calls it "Suggested UBERON concepts: heart"; UBERON calls it heart**